What everyone's not considering is what LP would accept as a minimum from Merck, or anyone else. I suspect it's nearly 100 times the current price. No company would pay that sort of premium. What a company, one that knows her number, would say is, let's talk when your share price is approach half of what you're demanding.
Meanwhile, Merck and others may very well agree to run trials that utilize DCVax-L. In some cases after it's approved they may purchase it from the company. In others they may co-sponsor the trial with the company. It will also be possible that the company will want to run trials exclusively, purchasing a product they want to use from another company. The primary thing is no stock would be part of any of these agreements, at least not at anywhere near current prices.
I'm still a believer that by year's end we'll have a share price in the $1 to $5 range, depending on the news between now and then. If our price is near my high, perhaps a small percentage of stock could be acquired by a BP trial partner at say $10.
Gary
Bullish
Market Data 
Markets 
AI
